Venus Remedies Renews GMP Certification in Ukraine

Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) has successfully renewed its Good Manufacturing Practices (GMP) certification from Ukraine’s State Service on Medicines and Drugs Control. This renewal pertains to the company’s Unit-II facility located in Baddi, Himachal Pradesh, which manufactures cephalosporin, non-cephalosporin (carbapenem), and oncology parenteral injections in both liquid and lyophilised forms.

Strengthening Global Regulatory Standing

The renewed certification marks a significant advancement for Venus Remedies, reinforcing its regulatory credentials in Ukraine and extending its reach across Pharmaceutical Inspection Co-operation Scheme (PIC/S) markets. As a member of PIC/S—a collaborative network of 56 countries spanning Europe, Asia, Oceania, and the Americas—Ukraine serves as a strategic gateway for broader international access.

“This milestone not only reinforces our foothold in the Ukrainian market but also facilitates deeper penetration into PIC/S markets, significantly enhancing our international growth prospects,” noted Saransh Chaudhary, President – Global Critical Care and CEO – Venus Medicine Research Centre.

Venus Remedies has already established a strong presence in 32 PIC/S countries, including South Africa, Thailand, Malaysia, Saudi Arabia, and Australia, underlining the company’s consistent global engagement and compliance.

Unlocking Growth in Strategic Markets

Ukraine’s pharmaceutical sector is projected to grow at a CAGR of 3.9%, reaching a market size of USD 822.26 million by 2029. With a track record of more than two decades in the region and 44 registered products, Venus Remedies views the GMP renewal as a key catalyst for further expansion within Ukraine and the larger Asia-CIS corridor.

“Ukraine continues to be a key strategic market for us. This renewed GMP certification enhances our credibility with regulators and partners across the region,” stated Aditi K. Chaudhary, President – International Business.

World-Class Infrastructure and Global Accreditations

The certified Unit-II facility is equipped with advanced infrastructure and cutting-edge technologies to address complex therapeutic requirements. This facility forms an integral part of Venus Remedies’ global manufacturing ecosystem, which is recognised by major regulatory authorities, including:

• EU-GMP (INFARMED)
• SAHPRA
• WHO-GMP
• UNICEF
• TGA (Australia)
• INVIMA (Colombia)

Additionally, the company adheres to international quality and safety standards such as ISO 9001, ISO 14001, and ISO 45001.

Company Profile

Ranked among the top 10 fixed-dosage injectable manufacturers globally, Venus Remedies operates nine state-of-the-art facilities across Panchkula, Baddi, and Werne (Germany). The company maintains a commercial footprint in over 90 countries, offering a diversified portfolio of 75 products. It is also a recognised leader in antimicrobial resistance (AMR) research through its Venus Medicine Research Centre (VMRC), and actively contributes to global initiatives such as GASAR, the PLEA Trust, and the AMR Industry Alliance.

A Step Towards Strategic Global Integration

This renewed GMP certification not only reaffirms Venus Remedies’ commitment to manufacturing excellence but also strategically positions the company for continued growth across regulated international markets. As the company deepens its global footprint, this milestone further enhances its role as a trusted pharmaceutical partner on the world stage.

Disclaimer: This content is only for informational purpose. It does not make any recommendation to act or invest. Please read the offer documents carefully before investing. Investments are subject to market risks and other risks. There is no guarantee of the actual returns that will be given.